Investigational drug · Phase 3
QL1207H
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Neovascular Age-Related Macular Degeneration (nAMD).
Phase 3Last checked: Nov 19, 2026Latest source record: Mar 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "QL1207H"
First trial start
2026
Mar 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "QL1207H", any sponsor or status.
Conditions studied
As listed on its trial records.
- Neovascular Age-Related Macular Degeneration (nAMD)
Approved drugs for the same conditions: Wet macular degeneration · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "QL1207H" as an intervention, largest first.
- A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular DegenerationPivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07489586 · 356 participants (planned) · Start Mar 2026 · Primary completion Dec 2026
Drug: QL1207H injection; Aflibercept 8 mg · For: Neovascular Age-Related Macular Degeneration (nAMD)
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Neovascular Age-Related Macular Degeneration (nAMD)
- 4D-1503E10 vg, eyePhase 35 trials
4D Molecular Therapeutics · Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
- OTX-TKIaxitinib implantPhase 33 trials
Ocular Therapeutix, Inc. · Neovascular Age-related Macular Degeneration, Neovascular Age-Related Macular Degeneration, Neovascular Age-Related Macular Degeneration (nAMD)
- KHK4951Phase 22 trials
Kyowa Kirin Co., Ltd. · Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.